Radius Health (RDUS) Trading Up 6.7%
Shares of Radius Health Inc (NASDAQ:RDUS) traded up 6.7% on Thursday . The stock traded as high as $36.93 and last traded at $36.12. 1,310,321 shares traded hands during mid-day trading, an increase of 35% from the average session volume of 967,825 shares. The stock had previously closed at $33.86.
Several analysts have recently weighed in on the company. Cantor Fitzgerald reissued a “buy” rating and issued a $58.00 target price on shares of Radius Health in a report on Thursday. BidaskClub raised Radius Health from a “sell” rating to a “hold” rating in a report on Wednesday, January 10th. Zacks Investment Research raised Radius Health from a “sell” rating to a “hold” rating in a report on Monday, January 8th. Citigroup assumed coverage on Radius Health in a report on Wednesday, December 6th. They issued a “neutral” rating and a $30.00 target price for the company. Finally, ValuEngine raised Radius Health from a “strong sell” rating to a “sell” rating in a report on Friday, December 1st. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating and five have given a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus price target of $48.00.
The stock has a market cap of $1,620.00, a PE ratio of -6.65 and a beta of 1.10. The company has a debt-to-equity ratio of 0.53, a quick ratio of 12.79 and a current ratio of 12.87.
Radius Health (NASDAQ:RDUS) last issued its quarterly earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($1.31) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.28) by ($0.03). The company had revenue of $13.50 million during the quarter, compared to analysts’ expectations of $6.90 million. During the same quarter in the previous year, the business earned ($1.07) EPS. equities analysts forecast that Radius Health Inc will post -5.57 earnings per share for the current year.
In related news, insider Jesper Hoiland purchased 6,800 shares of the company’s stock in a transaction that occurred on Tuesday, November 7th. The shares were purchased at an average price of $29.04 per share, for a total transaction of $197,472.00. Following the transaction, the insider now directly owns 12,900 shares of the company’s stock, valued at approximately $374,616. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, major shareholder Growth N. V. Biotech purchased 50,000 shares of the company’s stock in a transaction that occurred on Wednesday, October 25th. The stock was bought at an average price of $32.85 per share, for a total transaction of $1,642,500.00. Following the transaction, the insider now directly owns 5,548,799 shares in the company, valued at $182,278,047.15. The disclosure for this purchase can be found here. Insiders purchased a total of 158,578 shares of company stock worth $4,659,916 in the last 90 days. 15.00% of the stock is currently owned by insiders.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. BB Biotech AG increased its position in Radius Health by 11.0% during the 2nd quarter. BB Biotech AG now owns 5,038,799 shares of the biopharmaceutical company’s stock worth $227,905,000 after purchasing an additional 498,400 shares during the period. Farallon Capital Management LLC increased its position in Radius Health by 18.3% during the 2nd quarter. Farallon Capital Management LLC now owns 3,686,300 shares of the biopharmaceutical company’s stock worth $166,731,000 after purchasing an additional 569,300 shares during the period. Vanguard Group Inc. increased its position in Radius Health by 4.5% during the 2nd quarter. Vanguard Group Inc. now owns 3,145,717 shares of the biopharmaceutical company’s stock worth $142,281,000 after purchasing an additional 135,071 shares during the period. BlackRock Inc. increased its position in Radius Health by 10.0% during the 2nd quarter. BlackRock Inc. now owns 2,893,641 shares of the biopharmaceutical company’s stock worth $130,881,000 after purchasing an additional 262,896 shares during the period. Finally, State Street Corp increased its position in Radius Health by 12.9% during the 2nd quarter. State Street Corp now owns 1,867,531 shares of the biopharmaceutical company’s stock worth $84,473,000 after purchasing an additional 213,399 shares during the period.
About Radius Health
Radius Health, Inc is a biopharmaceutical company. The Company is focused on the developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company’s lead investigational product candidate, TYMLOS (abaloparatide-SC) injection is developed for the treatment of postmenopausal women with osteoporosis at high risk for fracture.
Receive News & Ratings for Radius Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health and related companies with MarketBeat.com's FREE daily email newsletter.